| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Betulin diacetate targets HIV and cancer cells. It acts on mitochondrial and oxidative pathways. Resistance may develop through enhanced antioxidant enzyme expression. It is a triterpenoid with multiple biological activities.
|
|---|---|
| ln Vitro |
In vitro, betulin diacetate demonstrates anti-HIV and anti-cancer activity. It acts on mitochondrial and oxidative pathways. It inhibits cancer cell proliferation and induces apoptosis in sensitive cell lines. It shows activity against HIV in cell-based assays. Detailed IC50 values are available in the primary literature.
|
| ln Vivo |
In vivo, betulin diacetate is used in the treatment of cancer and HIV. It has been studied in preclinical models of cancer and viral infection. It acts on mitochondrial and oxidative pathways. Detailed in vivo efficacy data including tumor growth inhibition and viral load reduction are available in preclinical literature.
|
| Enzyme Assay |
In vitro enzyme assays for betulin diacetate typically involve measuring its effects on mitochondrial function and oxidative pathways. Mitochondrial respiration is assessed using oxygen consumption measurements. Oxidative stress markers are measured. Anti-HIV activity is evaluated by measuring viral replication in infected cells. Anti-cancer activity is assessed by cell viability assays.
|
| Cell Assay |
Cell-based assays for betulin diacetate involve culturing cancer cell lines or HIV-infected cells in appropriate media. Cells are treated with betulin diacetate at concentrations ranging from 0.1 µM to 50 µM for 24-72 hours. Cell viability is assessed by MTT or CellTiter-Glo assays. HIV replication is measured by p24 antigen ELISA or viral RNA quantification. Apoptosis is evaluated by flow cytometry.
|
| Animal Protocol |
In vivo animal experiments for betulin diacetate typically involve administration to tumor-bearing mice or HIV-infected animal models via oral gavage or intraperitoneal injection. Tumor growth inhibition or viral load reduction is monitored. Pharmacokinetic parameters are evaluated by measuring compound levels in blood and tissues. Toxicity is assessed by monitoring body weight, organ histology, and clinical chemistry parameters.
|
| ADME/Pharmacokinetics |
Betulin diacetate (molecular weight 526.79, formula C34H54O4) is a triterpenoid. It has moderate lipophilicity and oral bioavailability. It is metabolized in the liver and excreted via bile and urine. Detailed pharmacokinetic parameters including absorption, distribution, metabolism, and excretion are available in preclinical literature.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data are specifically available for betulin diacetate from the search results. As a natural product derivative, it is expected to have a manageable safety profile. Resistance may develop through enhanced antioxidant enzyme expression. Comprehensive toxicological evaluation has likely been conducted in preclinical development.
|
| References | |
| Additional Infomation |
According to reports, betulinic acid diacetate has been found in Trichosanthes kirilowii, Trichosanthes cucumeroides, and other organisms with available data.
Betulin diacetate (CAS#: 1721-69-3) is a pentacyclic triterpenoid and betulin derivative. It has anti-HIV and anti-cancer activity. It acts on mitochondrial and oxidative pathways. Molecular weight: 526.79, formula: C34H54O4. It is found naturally in birch bark. |
| Molecular Formula |
C34H54O4
|
|---|---|
| Molecular Weight |
526.79016
|
| Exact Mass |
526.402
|
| CAS # |
1721-69-3
|
| PubChem CID |
236415
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
548.1±23.0 °C at 760 mmHg
|
| Melting Point |
221-223ºC
|
| Flash Point |
258.0±21.0 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.526
|
| LogP |
10.8
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
38
|
| Complexity |
998
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)C)C)COC(=O)C
|
| InChi Key |
MIROITGPMGDCGI-MQXQNARFSA-N
|
| InChi Code |
InChI=1S/C34H54O4/c1-21(2)24-12-17-34(20-37-22(3)35)19-18-32(8)25(29(24)34)10-11-27-31(7)15-14-28(38-23(4)36)30(5,6)26(31)13-16-33(27,32)9/h24-29H,1,10-20H2,2-9H3/t24-,25+,26-,27+,28-,29+,31-,32+,33+,34+/m0/s1
|
| Chemical Name |
[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-acetyloxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-3a-yl]methyl acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~5 mg/mL (~9.49 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8983 mL | 9.4914 mL | 18.9829 mL | |
| 5 mM | 0.3797 mL | 1.8983 mL | 3.7966 mL | |
| 10 mM | 0.1898 mL | 0.9491 mL | 1.8983 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
